Partial PTEN deletion is linked to poor prognosis in breast cancer
Open Access
- 16 December 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 15 (1), 963
- https://doi.org/10.1186/s12885-015-1770-3
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomasBritish Journal of Cancer, 2012
- MGMT and PTEN as potential prognostic markers in breast cancerExperimental and Molecular Pathology, 2012
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesisNature Genetics, 2009
- Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostateNature Genetics, 2009
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Mutation ofPten/Mmac1in mice causes neoplasia in multiple organ systemsProceedings of the National Academy of Sciences of the United States of America, 1999
- High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in miceCurrent Biology, 1998